Download RTF - OTC Markets

FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
For the month of May, 2016
TBG DIAGNOSTICS LIMITED
(Translation of registrant’s name into English)
Level 18, 101 Collins Street, Melbourne, Victoria, Australia 3000
(Address of principal executive offices)
[Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
[Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
[If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ☐
Attached as Exhibit 99.1 is a copy of the Company’s Announcement from May 30 th , 2016
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
TBG Diagnostics Limited
Date: May 30 th , 2016
By:
2
Blair Lucas, Company Secretary
EXHIBIT INDEX
Exhibit Number
Exhibit 99.1
Description
TBG Diagnostics Commences HLA Kit Sales with Leading US Cancer Treatment Centre MD Anderson, University
of Texas
3
Exhibit 99.1
ABN 82 010 975 612
Level 18, 101 Collins
Street
Victoria 3000 Australia
Telephone: + 61 7 3273
9133
Facsimile: + 61 7 3375
1168
www. tbgbio.com/public/
TBG Diagnostics C ommences HLA K it S ales with Leading US Cancer Treatment C entre M D Anderson,
University of Texas
● MD Anderson now using HLA kits purchased from TBG Taiwan
● MD Anderson is one of three major US cancer treatment centres
● MD Anderson to use TBG’s HLA products to provide histocompatibility testing services for transplantation
Melbourne, Australia, 30 May 2016. The Board of TBG Diagnostics Limited (ASX: TDL, OTC: PGLA) (the Company) is pleased to
announce it has commenced supply of HLA Typing kits to University of Texas MD Anderson Cancer Centre (MD Anderson) and has
completed two shipments of the kits to date.
TBG’s HLA Typing kits will be utilised by MD Anderson for histocompatibility testing services. Histocompatibility testing is applied to whole
organ, tissue, or stem cell transplants where compatibility of genes groups known as human leukocyte antigens (HLA) is imperative for
transplant tissue acceptance.
Apart from histocompatibility testing services, the MD Anderson laboratory is also involved in addressing fundamental, scientific studies such
as the study of population genetics of the HLA system, the definition of epitopes in the HLA molecular and the selection of peptides by
different HLA molecules.
TBG Diagnostics Group COO, Mr Eugene Cheng commented, “This sales deal with MD Anderson for the supply of our HLA Typing Kits,
endorses the high quality and leading edge product that we develop at TBG Diagnostics. We are very proud that our products are employed at
the forefront of medical services at varied diagnostic and healthcare centres around the world. TBG looks forward to building on this
relationship with such a prestigious centre as MD Anderson.”
ENDS
For more information:
Blair Lucas
Company Secretary
+61 7 3273 9133
+61 403 358 638
This release contains forward-looking statements that are based on current management expectations. These statements may differ materially
from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with development and
manufacture, risks inherent in the extensive regulatory approval process mandated by, amongst others, the United States Food and Drug
Administration , the China Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the
necessary approvals for clinical testing, patient recruitment, sample collection, delays in the conduct of clinical trials, market acceptance of
TBG products, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the
Company’s filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can
be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the
Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.
About TBG Diagnostics
TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. We are focused on the
development, manufacture and marketing of molecular diagnostic kits, instruments and services
TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and
manufactures:
● Nucleic Acid Test (NAT) products
● HLA typing reagents based on NAT technologies
● Automation systems for NAT operations
● IVD-related NAT kits and services
Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong
and Singapore. Operating in the rapidly growing IVD market - US$53 billion in 2013 and expected to reach US$74.7 billion by 2020 Targeting
further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for
oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases
About MD Anderson
The University of Texas MD Anderson Cancer Centre is one of the original three comprehensive cancer centres in the United States established
by the National Cancer Act of 1971. It is both a degree-granting academic institution and a cancer treatment and research centre located at the
Texas Medical Centre in Houston, Texas, United States. It is one of the few hospitals in the United States affiliated with two major research
based medical schools: The University of Texas Medical School at Houston, which is a part of the larger University of Texas Health Science
Centre at Houston, and Baylor College of Medicine.
As of 2015, MD Anderson Cancer Centre was ranked #1 for cancer care in the "Best Hospitals" survey published in U.S. News & World
Report. MD Anderson is widely regarded as among the best cancer hospitals in the United States.
MD Anderson was created by an act of the Texas Legislature in 1941, making it a part of The University of Texas System. Today it is one of
45 Comprehensive Cancer Centres designated by the National Cancer Institute. The cancer centre provided care for about 127,000 patients in
Fiscal Year 2014 and employs more than 20,000 people. It has an endowment of $486 million as of November 30, 2014.